News Room

Read the latest news and press releases from Evidera and browse our archive.

May 08, 2017

PPD Creates Dedicated Real-world Research and Market Access Unit by Combining Medical Affairs Research Operations and Evidera

WILMINGTON, N.C., May 8, 2017 — Pharmaceutical Product Development, LLC (PPD), a leading global contract research organization (CRO), today announced the creation of a dedicated unit combining its medical affairs research operations (MARO) team and Evidera, the provider of evidence-based solutions to demonstrate the real-world effectiveness, safety and value of biopharmaceutical and biotechnology products. PPD […]

Read More

September 06, 2016

PPD Completes Evidera Acquisition, Establishes Global Leader in Real-World Research

WILMINGTON, N.C., September 6, 2016 — Pharmaceutical Product Development, LLC (PPD), a leading global contract research organization (CRO), today announced the completion of its acquisition of Evidera, a leading provider of evidence-based solutions to demonstrate the real-world effectiveness and value of biopharmaceutical products. The acquisition unites two best-in-class research companies, creating transformative opportunities for clients of […]

Read More

August 30, 2016

Evidera Among the Top 50 Consulting Firms to Work for in Vault’s 2017 Ranking

Evidera was ranked among the best consulting firms to work for in the 2017 Vault Consulting 50, capturing the #46 spot among larger consulting firms such as Deloitte, Bain, McKinsey, and BCG. Evidera also ranked among Vault’s 2017 Top 25 Best Boutique Consulting Firms. Vault surveyed more than 17, 000 practicing consultants worldwide to create […]

Read More

August 09, 2016

Evidera to Join PPD, Creating the Global Leader in Real-World Research

WILMINGTON, NC, August 9, 2016 — Pharmaceutical Product Development, LLC (PPD), a leading global contract research organization (CRO), today announced it has entered into an agreement to acquire Evidera, a leading provider of evidence-based solutions to demonstrate the real-world effectiveness and value of biopharmaceutical products. The acquisition will further strengthen the peri- and post-approval capabilities of […]

Read More

June 13, 2016

Evidera welcomes Dr. Colleen A. McHorney as a Senior Research Leader in Outcomes Research

BETHESDA, MD, June 13, 2016 — Evidera, a leading provider of evidence-based solutions for the healthcare industry, is pleased to announce that Colleen A. McHorney, PhD – an internationally- recognized thought leader in the fields of health outcomes assessment and medication adherence – has joined Evidera as a Senior Research Leader in its Outcomes Research […]

Read More

June 06, 2016

Evidera Congratulates the COPD Foundation on the Inclusion of the SGRQ in the New FDA COPD Draft Guidance

BETHESDA, MD, June 6, 2016 — Evidera would like to extend an enthusiastic congratulations to the COPD Foundation and their Chronic Obstructive Pulmonary Disease (COPD) Biomarker Qualification Consortium (CBQC). Thanks to their efforts over the past five years, the FDA’s updated draft guidance for COPD drug development, “Chronic Obstructive Pulmonary Disease: Developing Drugs for Treatment, […]

Read More

April 28, 2016

COPD FOUNDATION AND EVIDERA AWARDED BEST PERSONALIZED MEDICINE ADVANCE OR APPLICATION AT THE CLINICAL & RESEARCH EXCELLENCE (CARE) AWARDS

BETHESDA, MD, April 28, 2016 — Evidera and the COPD Foundation were awarded Best Personalized Medicine Advance or Application at Informa’s 2016 Clinical & Research Excellence (CARE) Awards, held on April 27 in Boston, MA. Evidera, a global leader in health economics, outcomes research, market access, data analytics and epidemiology, and the Foundation’s COPD Biomarker […]

Read More

April 06, 2016

Evidera Advances The Use Of DICE: A Health Economic Modeling Approach Designed To Meet HTA Requirements

BETHESDA, MD, April 6, 2016 — Evidera, a global leader in generating and communicating evidence of product value for life science companies, is pleased to announce new modeling capabilities using Discretely-Integrated Condition Event (DICE) simulation. DICE is the first modeling technique specifically designed to meet decision-analytic modeling needs for health technology assessment (HTA). It is a […]

Read More

April 05, 2016

Dr. Jaime Caro Wins ISPOR’s 2016 Marilyn Dix Smith Leadership Award

Evidera is pleased to announce that Dr. Jaime Caro, Chief Scientist, is the recipient of ISPOR’s 2016 Marilyn Dix Smith Leadership Award.  Marilyn Dix Smith was the Founding Executive Director of ISPOR, conceiving and building the society focused on pharmacoeconomics and outcomes research.  Marilyn’s vision was to create an organization that identifies, supports and provides […]

Read More

March 09, 2016

FDA RELEASES DRAFT GUIDANCE ON USE OF THE “E-RS: COPD” TO MEASURE RESPIRATORY SYMPTOMS IN STABLE COPD

BETHESDA, MD, March 09, 2016 — Evidera, a leading provider of evidence‐based solutions for the healthcare industry, is pleased to announce that the Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA), released its second draft qualification guidance document for a patient-reported outcome (PRO) measure: Evaluating Respiratory Symptoms in Chronic Obstructive […]

Read More

February 01, 2016

Evidera Congratulates the ISPOR MCDA Task Force on New Report Highlighting Growing Relevance of MCDA

The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) has published a new report entitled “Multiple Criteria Decision Analysis for Health Care Decision Making – An Introduction: Report 1 of the ISPOR MCDA Emerging Good Practices Task Force, ” in its January/February 2016 issue of Value in Health (Volume 19, Issue 1). MCDA is increasingly […]

Read More

January 14, 2016

Evalytica Recognized Among Top 10 Analytics Solution Providers in 2016 by Pharma Tech Outlook

SAN FRANCISCO, CA, January 14, 2016 — Evalytica™ makes it into Pharma Tech Outlook’s Top 10 Analytics Solution Providers list for its expertise in redefining the intersection of technology and healthcare analytics with its innovative next generation software for real-world evidence development. This annual list showcases the Top 10 Analytics Solution Providers 2016. The positioning is […]

Read More

December 22, 2015

A New Office for Evidera in Harrisburg, PA

HARRISBURG, PA, December 16, 2015 — Evidera announces the opening of a Harrisburg, PA office. This office represents an expansion of Evidera’s San Francisco based Technology Solutions group, focused on redefining the intersection of technology and healthcare analytics with innovative next generation software for real-world evidence development. The new office will house technical experts who […]

Read More

October 01, 2015

Evidera Welcomes Dr. Bryan Luce as a Senior Advisor

BETHESDA, MD, October 1, 2015 — Evidera, a leading provider of evidence-based solutions for the healthcare industry, is pleased to announce that Dr. Bryan Luce, PhD, MS, MBA has joined Evidera as a Senior Advisor. In this role Dr. Luce will provide thought leadership and strategic guidance to the Evidera executive leadership team, as well […]

Read More

September 21, 2015

Evidera Announces Evalytica™, Next-Generation, Cloud-Based Software for Fast, Transparent Analysis of Healthcare Data

BETHESDA, MD, September 21, 2015 — Evidera, a leading provider of evidence-based solutions for the healthcare industry, is pleased to announce Evalytica™, a new software platform designed to support near real-time analyses of virtually any type of real-world data source, including claims, electronic medical records, and registry data. Evalytica™ uses standard data formats and published analytic […]

Read More

September 15, 2015

Evidera Launches Its Alzheimer’s Disease ACE

BETHESDA, MD, September 15, 2015 — Evidera, a leading provider of evidence-based solutions for the healthcare industry, is pleased to announce the release of the first Alzheimer’s Disease ACE simulator. Bringing to bear more than two decades of experience in modeling AD, Evidera scientists have developed the AD ACE, a comprehensive multi-application disease simulator designed […]

Read More

July 15, 2015

Evidera congratulates the COPD Foundation on the FDA approval of the first COPD biomarker

BETHESDA, MD, July 15, 2015 — Evidera would like to extend an enthusiastic congratulations to the COPD Foundation and their COPD Biomarker Qualification Consortium (CBQC) on their work leading to the qualification of plasma fibrinogen as the first biomarker for COPD by the U.S. Food and Drug Administration (FDA). The use of this biomarker is expected to make it easier […]

Read More

May 11, 2015

EMA Releases Draft Opinion on Two Patient-Reported Outcome (PRO) Measures for Evaluating New Treatments for COPD

BETHESDA, MD, May 11, 2015 — Evidera, a leading provider of evidence‐based solutions for the healthcare industry, is pleased to announce the release of the European Medicines Agency’s (EMA) draft qualification opinion on the EXACT (Exacerbations of Chronic Pulmonary Tool) and E-RS (EXACT-Respiratory Symptoms), two patient-reported outcome (PRO) measures for evaluating treatment outcomes in COPD […]

Read More

November 06, 2014

Evidera to Give 55 Presentations at ISPOR European Congress, the Most of Any Attending Company

LONDON, UK, November 6, 2014 — Evidera, the global leader in health economics, outcomes research, market access, data analytics and epidemiology solutions, will participate in 55 presentations — the most of any attending company — at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual European Congress, Nov. 8-12, in Amsterdam, Netherlands. With approximately […]

Read More

October 08, 2014

Symphony Technology Group to Convene International Industry Panel to Discuss Improving Healthcare through Better Use of Big Data and Improved Analytics Tools

– Inaugural Healthcare Advisory Council Meeting held in Washington, DC– PALO ALTO, CA, October 8, 2014 — Leading physicians and healthcare executives recently convened to discuss leveraging big data across the healthcare industry to improve standards of care at the first-annual STG Healthcare Advisory Council meeting. The two-day event, titled “Delivering on the Promise of […]

Read More

May 29, 2014

Evidera’s Expertise Evident In More Than 40 Presentations At ISPOR

BETHESDA, MD, May 29, 2014 — Scientists and consultants from Evidera, a global leader in health economics, outcomes research, market access, data analytics and epidemiology solutions, will present more than 40 papers — the highest of any attending company — at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting in Montreal, Quebec, […]

Read More

April 29, 2014

Evidera Opens New European Headquarters With 100 Market Access And Evidence Experts

LONDON, UK, April 29, 2014 — Evidera, an industry leading pharmaceutical research and consulting business, today announced the opening of a new London office, consolidating two previous sites in the city and creating room for continued growth. Evidera provides health economics, outcomes research, market access and epidemiology services to the world’s top biopharmaceutical companies. The […]

Read More

January 14, 2014

Evidera Announces Release Of FDA Draft Guidance On Use Of The “EXACT” To Measure Symptoms Of COPD Exacerbations

BETHESDA, MD, January 14, 2014 — Evidera, a leading provider of evidence-based solutions for the healthcare industry, announced that the Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration, has released its first draft qualification guidance document for a patient-reported outcome (PRO) measure in drug development: Qualification of Exacerbations of Chronic Pulmonary […]

Read More

January 08, 2014

Archimedes, A Leader In Healthcare Simulation Is Acquired By Evidera, A Symphony Technology Group Company

PALO ALTO, CA. and BETHESDA, MD, January 8, 2014 — Symphony Technology Group (STG), a technology and services-focused private equity firm, and Evidera, a leading provider of evidence-based solutions for the healthcare industry, today announced the acquisition of Archimedes, a San Francisco-based healthcare modeling company and wholly owned subsidiary of Kaiser Permanente. No other terms […]

Read More

November 22, 2013

Evidera Awarded Best Market Access Drug Programme 2013 At The Rare & Orphan Advocacy And Research (ROAR) Awards

BETHESDA, MD, November 22, 2013 — Evidera, a global leader in health economics, outcomes research, market access, data analytics and epidemiology solutions, has been awarded Best Market Access Drug Programme 2013 in the Rare & Orphan Advocacy and Research (ROAR) Awards. The ROAR Awards were announced during the 4th Annual World Orphan Drug Congress Europe, […]

Read More

July 08, 2013

UBC’s HEOR/Market Access Division Acquired By Symphony Technology Group — Introducing Evidera

PALO ALTO, CA, July 8, 2013 — Symphony Technology Group (STG), a technology and services-focused private equity firm, today announced that it has acquired the health economics, health outcomes, market access and retrospective epidemiology and data analytics divisions of United BioSource Corporation (UBC), a wholly owned subsidiary of Express Scripts Holding Company. Terms of the […]

Read More
Back to Top